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Editorial on the Research Topic
Biomarkers to Disentangle the Physiological From Pathological Brain Aging
The worldwide increase of human life expectancy (“lifespan”) along with the concomitant rapid
population aging represents the major social phenomena of the last century. This has substantially
impacted our societies by virtue of the huge economic implications and public health challenges
(Lim et al., 2018). In order to promote healthy aging and further increase the years of life spent
without disabilities (“healthspan”) (Beard et al., 2016; Olshansky, 2018), it is necessary to delve
deep into the biology of aging and disentangle the mechanisms that underpin the physiological
processes from those leading to pathological manifestation.
In this context, dementia as well as others common neurodegenerative diseases are strongly
correlated with age. Although advancing age represents the major risk factor for cognitive decline,
dementia is not an inevitable consequence of long life, as clearly demonstrated by centenarians who
managed to preserve normal cognitive performance despite their age (Arosio et al., 2017). Against
this backdrop, the ongoing “biomarker revolution” has been instrumental in transforming the
landscape of medical research and practice. The relevance of biomarkers to the field of physiological
and pathological brain aging is underscored by two considerations. Firstly, the relative lack of
accessibility of brain issue for diagnostic or research purposes, and secondly, the understanding that
neurodegenerative diseases are often characterized by a long preclinical phase has fuelled transition
toward a biology-grounded framework and definition such as the NIA-AAResearch Framework for
Alzheimer’s disease (AD) (Jack et al., 2018).
However, the available biomarkers currently used for AD generally describe single aspects of
the patient’s state and are only modestly associated with clinically meaningful manifestations. The
combination of biomarkers capable of assessing the “real” biological age of the individual may
thus represent a viable strategy to support the identification of disease-specific trajectories and,
in parallel, provide insights about the aging phenomenon. The present Research Topic is therefore
timely in advancing the ongoing discourse beyond the need of disentangling “physiological” from
“pathological” brain aging to deepening existing understanding and offering new vistas for further
development in the field.
Using cerebrospinal fluid (CSF) biomarkers for AD as a paradigmatic example, Canevelli et al.
discussed the methodological issues and challenges that pertain to four key areas: (1) definition of
reference values; (2) identification of reference standards specific for the disease of interest (i.e.,
AD); (3) proper inclusion and contextualization within the diagnostic process; and (4) statistical
processes supporting the whole framework. They concluded that various methodological issues
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remain to be addressed in order to perform an adequate and
complete clinical validation of candidate CSF biomarkers for AD.
Five papers in this Research Topic shed precious insights into
emerging biomarkers from readily available biological samples.
In their comprehensive review, D’Anca et al. explored the
current understanding of role of exosomes in physiological
aging and age-related neurodegenerative diseases such as AD,
Parkinson’s Disease (PD) and frontotemporal dementia. Insights
from the study of exosomes and their genetic cargo (such as
lipid, proteins, mRNAs, and ncRNAs) have elevated their role
beyond mere waste disposal function to fundamental mediators
of intercellular communication, akin to the proverbial double-
edge sword serving as Trojan horses of neurodegeneration
vis-à-vis providing neuroprotection from neurodegeneration.
Exosomes can be detected in many biological fluids, enhancing
their appeal as potential sources of biomarkers suitable for use in
clinical practice.
Similarly, Tay et al. prospectively studied serum levels
of Dickkopf-1 (Dkk-1) in older adults with mild cognitive
impairment (MCI) and mild-to-moderate AD. The findings
revealed that Dkk-1 increased significantly from baseline
amongst progressors, while non-progressors exhibited
decremental Dkk-1 at 1 year, alluding to the putative role
in MCI and AD progression of dysfunctional Wnt signaling
through Dkk-1 antagonism. Sun et al. demonstrated that cofilin
2 expression was significantly increased in AD patients and
different AD models (animal and cell), with good discriminatory
ability that distinguish AD from healthy subjects and in
differential diagnosis of AD from vascular dementia. By studying
391 cognitively normal subjects aged 23–91 years from Asia,
USA and Europe, Lue et al. characterized the relationship
between age and three plasma AD core biomarkers (Aß40,
Aß42, and t-Tau), provided the normal ranges of Aß species and
t-Tau in plasma, and explicated the development of a dynamic
relationship between these biomarkers from middle to old age.
Lastly, Falconi et al. investigated the transcriptional regulation of
the Adenosine A2A receptors (A2ARs) gene in human peripheral
blood mononuclear cells obtained from PD patients and in the
striatum of the 6-hydroxydopamine-induced PD mouse model.
They reported an increase in A2AR mRNA expression and
protein levels in both human cells and mice that is accompanied
by histone acetylation and DNA methylation, paving the way for
therapeutic interventions in future.
Another prominent theme in this Research Topic was
the contribution of advanced neuroimaging biomarkers. For
instance, in terms of explicating mechanisms that underpin
underlying pathophysiological processes, Wang, Li et al.
shed light on the neural mechanisms of working memory
deficits in MCI. By combining static and temporal dynamic
examination of amplitude of low-frequency fluctuations (ALFF)
from functional magnetic resonance imaging, they reported
background network changes especially in the parietal and
temporal lobes during working memory states in MCI. Similarly,
Pur et al. enhanced understanding by demonstrating the
moderating effect of cortical thickness on blood oxygen level-
dependent (BOLD) signal variability age-related changes and
highlight the importance of considering these effects when
evaluating BOLDSD alternations across the lifespan. Kobayashi
et al. examined whether dementia with Lewy Bodies (DLB)
follows an AD-type trajectory whereby amyloid-ß deposition
begins considerably before onset of dementia. They observed a
low amyloid load in REM sleep behavioral disorder, a prodromal
symptom of DLB, suggesting that this phenomenon does not
always precede the onset of cognitive decline in DLB. Lastly,
through the use of MRI voxel studies to examine neural
substrates, Wu, Geng et al. implicated the left-precentral cortex
and left inferior frontal gyrus areas that accounted for olfactory
impairment in a cohort of AD and MCI patients in the
Chinese Han population.
Other papers in this Research Topic illuminated the
knowledge gap in our understanding about the role of
misfolded protein accumulation in neurodegenerative diseases.
The extracellular accumulation of amyloid beta (Aβ) peptide is
the paradigmatic example, with recent neuroimaging capabilities
in tracking Aβ deposition a fascinating way to distinguish if
the observed Aβ accumulation is characteristic of the aging
process or conversely, an etio-pathogenetic mechanism of AD
(Canevelli et al., 2017). Hatashita et al. examined [18F]-
flutemetamol (FMM), a fluorinated derivative of the prototypic
[11C]-Pittsburgh Compound B (PIB), and demonstrated that
[18F]-FMM PET imaging can track longitudinal changes in Aβ
deposition across the AD spectrum, similarly to [11C]-PIB PET.
Notably, they reported that the increase in Aβ deposition is not
constant across the AD spectrum but faster in the predementia
stage (Hatashita et al.). Using dynamic [18F] florbetapir PET,
Verfaillie et al. investigated the possibility that self-perceived
cognitive decline (SCD), generally associated with a three- to
six-fold increased risk of AD, may reflect an early symptom
of Aβ related pathology. They concluded that Aβ load was
associated with SCD related worries rather than subjective
cognitive functioning per se (Verfaillie et al.).
Other papers highlight advances in neuroimaging techniques
that pave the way for fresh perspectives in early diagnosis of
AD. Utilizing sophisticated measurements of cortical thickness
with 3.0-Tesla MRI in a large population of cognitively normal
individuals and patients with AD continuum, Lee et al. described
an age-dependent cortical thinning with relative sparing of the
precuneus and inferior temporal regions. In contrast, late-stage
amnestic MCI and moderate to severe AD were associated
with widespread cortical thinning including the precuneus and
inferior temporal regions (Lee et al.). Furthermore, the study
by Wu, Xu et al. provides proof-of-concept evidence that a
topological examination of the structural connectivity networks
with different parcellation schemes can provide important
complementary AD-related information and thus contribute to
a more accurate and earlier diagnosis of AD. Another promising
technique involved amide proton transfer (APT) imaging as an
imaging modality to detect tissue protein. In fact, Wang, Chen
et al. adopting a modified APT method (APTSAFARI on a
7.0T animal MRI scanner) in animal models, demonstrated that
APT imaging could potentially provide molecular biomarkers for
non-invasive diagnosis of AD. Using direct non-invasive brain
network electrophysiological imaging, Zifman et al. established
that this new technique can be used both to monitor brain
aging and for early detection of abnormal changes leading
to neurodegeneration.
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Bioimaging techniques are also useful for the differential
diagnosis of PD. Dopamine-transporter SPECT (DAT-SPECT),
diffusion tensor imaging (DTI), and structural magnetic
resonance imaging (sMRI) provide unique information about
neurotransmitters and microstructural properties in PD. The
longitudinal study of Lorio et al. described how the combination
of these imaging modalities can be used as biomarkers of PD
severity and prognosis which can be potentially useful for clinical
trials. Likewise, Pelizzari et al. proposed the concomitant use of
DTI to detect brain tissue microstructural alterations, together
with arterial spin labeling (ASL) MRI to analyse abnormal
cerebral perfusion patterns in PD. The study showed that DTI
is a more sensitive technique than ASL to detect alterations
in the basal ganglia in the early phase of PD, suggesting that
a relationship between microstructural integrity and perfusion
changes in the caudate may be present (Pelizzari et al.).
Papers in this Research Topic also addressed the issue of age-
associated co-morbidities, particularly cardiovascular diseases,
and related risk factors such as Type II diabetes mellitus (T2DM),
which often confound the measurement and interpretation
of neurodegenerative biomarkers. Exploring the association
between white matter hyperintensities with higher Intima-media
thickness (IMT) and blood pressure variability, Chen et al.
developed an innovative predictive model to evaluate white
matter burden in hypertensive patients using metrics in 24-h
ambulatory BP monitoring (systolic blood pressure [SBP] and
daytime SBP standard deviation) and carotid ultrasound IMT.
Leveraging upon the diagnostic potential of diabetic retinopathy
(DR) afforded by its time-course which precedes the occurrence
of T2DM cognitive impairment, Lu et al. verified the correlation
between DR from fundus examination and T2DM cognitive
impairment. They further established using magnetic resonance
spectroscopy (1H-MRS) that this may be attributed to bilateral
changes in hippocampal brain metabolism, alluding to the
potential role of 1H-MRS for early diagnosis of T2DM cognitive
impairment (Lu et al.).
A major pathogenetic influence of co-morbidities or their
treatment that have emerged in recent years is that of
concomitant inflammatory processes that may alter disease
manifestation and confound biomarker interpretation. An
example is the cognitive decline observed in some HIV
subjects during ART-mediated viral suppression, a phenomena
which has been ascribed to cytokine-mediated inflammation.
Bandera et al. suggested an omics approach (transcriptomics,
proteomics, and metabolics) to accelerate the discovery of
reliable biomarkers of HIV-associated neurocognitive disorders
in the current era of virological suppression with modern
anti-retroviral therapy. Similarly, persistent inflammation has
been implicated as a cardinal mechanism of neurocognitive
impairment and neurodegenerative features in Multiple Sclerosis
(MS). Jakimovski et al. reported the novel finding that almost half
the elderly subjects with MS are impaired on tests of cognitive
processing speed or verbal fluency. Since the deficit in verbal
fluency is not a typical hallmark of the cognitive profile associated
with MS, it may represent a unique trait of old persons with MS
neurocognitive profile (Jakimovski et al.).
Lastly, there is growing interest in the role of physical activity
and exercise as “medicine” that can be prescribed for brain health.
In their comprehensive review, Barha et al. underlined the role
of biological sex as a potential moderator in the relationship
between physical activity and brain health in older adults.
They suggested that different neurobiological mechanisms (e.g.,
neurotrophic factors, neuroplastic processes, hormones, and
neurotransmitter systems) as well as physiological adaptations
to physical activities could be responsible for the differences in
trajectories of decline observed in men and women (Barha et al.).
This highlights the importance of taking into consideration the
potent moderating influence of sex differences for both cognitive
and neural outcomes in future therapeutic and rehabilitative
interventions involving physical activity in older adults.
As guest editors for this Research Topic, we commend this
collection of 23 articles to our readers as a timely addition and
important contribution to the field. We are confident that this
will spur further discourse and open avenues for further research
into the rapidly evolving and fascinating area of biomarkers to
disentangle physiological from pathological brain aging.
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